GW Pharmaceuticals plc: GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Cannabidiol Oral Solution in Lennox-Gastaut Syndrome

- First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onse...

More From BioPortfolio on "GW Pharmaceuticals plc: GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Cannabidiol Oral Solution in Lennox-Gastaut Syndrome"